Jazz Pharmaceuticals Plc Stock Price, News & Analysis

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 2025 financial results with total revenues of $1.05 billion, up 2% year-over-year. The company announced leadership transition with Renee Gala appointed as President and CEO effective August 11. Key product performance included Xywav revenue growth of 13% to $415.3 million with 625 new patients added. The company faced challenges with GAAP net loss of $718.5 million, largely due to a $905.4 million IPR&D expense from the Chimerix acquisition.

Notable pipeline developments include Zepzelca's Priority Review for first-line ES-SCLC treatment and Ziihera's European approval for HER2-positive biliary tract cancer. The company updated its 2025 guidance, projecting total revenue of $4.15-$4.30 billion, representing 4% growth at midpoint. Jazz also executed $125 million in share repurchases during Q2.

Jazz Pharmaceuticals (NASDAQ: JAZZ), a global biopharma company, has announced it will release its 2025 second quarter financial results on Tuesday, August 5, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and provide business updates.

Participants are encouraged to register at least 15 minutes before the webcast through the company's website or direct registration link. A replay will be available in the Investors section of Jazz Pharmaceuticals' website. The company specializes in developing medicines for sleep disorders, epilepsy, and cancer treatments, with operations spanning multiple countries.

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that Renee Gala will become the company's new President and Chief Executive Officer, effective August 11, 2025. Gala, currently serving as President and COO, will succeed co-founder Bruce Cozadd, who will retire as CEO but continue as Board Chairperson.

Gala brings over 30 years of experience and has been instrumental in Jazz's transformation since joining as CFO in March 2020. Under her leadership as COO, the company achieved nearly 90% total revenue growth through portfolio diversification and strategic business development. The appointment follows a comprehensive succession planning process where the Board evaluated both internal and external candidates.

Jazz Pharmaceuticals (Nasdaq: JAZZ) has received conditional marketing authorization from the European Commission for Ziihera® (zanidatamab) for treating adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC) who have received at least one prior line of systemic therapy.

The approval is based on the Phase 2b HERIZON-BTC-01 trial results, which demonstrated significant efficacy in the largest study conducted to date in this population. Key findings include:

• Confirmed objective response rate (cORR) of 41.3% in the overall population
• Higher cORR of 51.6% in IHC 3+ tumor patients
• Median duration of response of 14.9 months
• Median overall survival of 18.1 months in IHC 3+ patients

Ziihera becomes the first HER2-targeted therapy authorized for HER2-positive BTC in the European Union. The approval extends to all EU Member States, Iceland, Norway, and Liechtenstein. Continued approval is contingent upon verification of clinical benefit in the ongoing Phase 3 HERIZON-BTC-302 trial.

Jazz Pharmaceuticals announced FDA Priority Review acceptance for Zepzelca in combination with atezolizumab as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The FDA set a PDUFA date of October 7, 2025. The application is supported by Phase 3 IMforte trial results, which showed significant improvements in both progression-free survival (5.4 vs 2.1 months) and overall survival (13.2 vs 10.6 months) compared to atezolizumab alone. The combination reduced disease progression/death risk by 46% and death risk by 27%. The treatment showed no new safety concerns and could provide a crucial new option for ES-SCLC patients, addressing a significant unmet medical need.

Jazz Pharmaceuticals (JAZZ) presented Phase 4 data for Xywav at SLEEP 2025, showcasing positive outcomes in narcolepsy treatment. The XYLO switch study demonstrated significant blood pressure reductions when patients switched from high-sodium to low-sodium oxybate, with a -4.1 mmHg change in 24-hour systolic blood pressure (P=0.0019). The study met its primary endpoint and key secondary endpoints, including improvements in daytime and resting blood pressure. Additionally, the DUET trial analysis showed effectiveness of Xywav at 9-12g doses, higher than the currently recommended 6-9g, with improvements in excessive daytime sleepiness. Both studies reported only mild to moderate treatment-emergent adverse events, consistent with Xywav's known safety profile. Xywav remains the only FDA-approved low-sodium oxybate for treating narcolepsy and idiopathic hypersomnia.

Jazz Pharmaceuticals announced breakthrough results from their Phase 3 IMforte study, showing Zepzelca (lurbinectedin) combined with atezolizumab significantly improved survival in extensive-stage small cell lung cancer (ES-SCLC) patients. The combination therapy, used as first-line maintenance treatment, reduced disease progression or death risk by 46% and demonstrated median overall survival of 13.2 months versus 10.6 months for atezolizumab alone. The study met both primary endpoints with statistically significant improvements in progression-free survival (5.4 vs 2.1 months) and overall survival. The combination therapy showed a manageable safety profile with no new safety signals, though it had higher treatment-related adverse events (83.5% vs 40.0%). This groundbreaking study is the first Phase 3 trial to show meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance, potentially establishing a new standard of care for patients.

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported significant long-term data for Ziihera (zanidatamab-hrii) in treating HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). The Phase 2 trial showed remarkable results with a median overall survival of 36.5 months and progression-free survival of 15.2 months in centrally confirmed HER2-positive patients. The study demonstrated an impressive 83.8% confirmed objective response rate with a median duration of response of 20.4 months. The treatment showed a manageable safety profile, with diarrhea (39%) and hypokalemia (22%) as the most common Grade 3-4 treatment-related adverse events. These results significantly outperform current standard care treatments, which typically show median survival of 15-20 months. The company expects top-line results from their pivotal Phase 3 HERIZON-GEA-01 trial in late 2025.

Jazz Pharmaceuticals (NASDAQ: JAZZ) will present nineteen abstracts, including eleven late-breaking abstracts, at SLEEP 2025 (June 8-11, Seattle), demonstrating comprehensive research on Xywav® treatment benefits. Key highlights include: • First interim results from the XYLO trial evaluating blood pressure changes in narcolepsy patients switching from high-sodium to low-sodium oxybate • Novel results from DUET trial assessing Xywav's effectiveness on multiple sleep parameters • Data on Xywav effectiveness and safety in narcolepsy patients with doses exceeding 9 grams • Results from CHIME study on real-world outcomes • Findings from INTREPID study on treatment patterns • LYRICAL study interim results showing symptom improvements and patient satisfaction The research emphasizes Jazz's commitment to advancing treatment for narcolepsy and idiopathic hypersomnia while focusing on patient-centric care and addressing cardiovascular risks through low-sodium formulation.